Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action LawsuitsNEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (
NASDAQ:ATYR), Marex Group PLC (
NASDAQ:MRX), Cepton, Inc. (
NASDAQ:CPTN), and MoonLake Immunotherapeutics (
NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTXNEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (
NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in MoonLake Lawsuit - MLTXNEW YORK - October 30, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (
NASDAQ: MLTX) of a class action securities lawsuit.
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming DeadlineNEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTXNEW YORK - October 29, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (
NASDAQ: MLTX) of a class action securities lawsuit.
Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics (MLTX) of a Class Action Lawsuit and an Upcoming DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics (MLTX) of a Class Action Lawsuit and an Upcoming DeadlineNEW YORK - October 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (
NASDAQ: MLTX) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action LawsuitsNEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (
NASDAQ:ATYR), Marex Group PLC (
NASDAQ:MRX), Cepton, Inc. (
NASDAQ:CPTN), and MoonLake Immunotherapeutics (
NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
MLTX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake ImmunotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
December 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MLTXNEW YORK - October 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (
NASDAQ: MLTX) of a class action securities lawsuit.
December 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MLTXSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Law Offices of Howard G. Smith Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (
NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (
NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action LawsuitsNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (
NASDAQ:ATYR), Marex Group PLC (
NASDAQ:MRX), Cepton, Inc. (
NASDAQ:CPTN), and MoonLake Immunotherapeutics (
NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
